We use cookies for a better user experience. Read our Privacy Policy

I Agree

Generic Injectables Market Insights, 2021-2031

Generic Injectables Market (Product Type: Large Molecule Injectables and Small Molecule Injectables; Application: Oncology, Infectious Diseases, Cardiology, Diabetes, Immunology, and Others; Container Type: Vials, Premix, Prefilled Syringes, Ampoules, and Others; and Route of Administration: Intravenous, Intramuscular, Subcutaneous, and Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2031

Price Cuts, Drug Launch Gain Prominence amid COVID-19 Pandemic

During the peak of the coronavirus outbreak amid the second wave in India, there had been an unprecedented demand for Remdesivir - an antiviral medication for the treatment of patients. Due to shortage in the supply of Remdesivir, companies in the generic injectables market such as Hetero Drugs, an Indian pharmaceutical company and one of world’s largest producer of anti-retroviral drugs, released its generic form of Remdesivir called Covifor.

Manufacturers in the generic injectables market are becoming future-ready by maintaining adequate supply chains to prevent vulnerabilities caused by potential COVID-19-like situations. Drug firms including Zydus Cadila are observed to significantly reduce the price of its generic version of Remdesivir namely Remdac. Companies are taking the advantage of government programs and financial schemes offered by the BFSI sector to streamline their business activities as per the volatile market sentiments.

generic injectables market infographic

To know the scope of our report Get a Sample on Generic Injectables Market

Challenges Posed by Syringe Inspection Affect Market Growth

Syringes are among the most difficult containers to inspect. With the largest vaccination effort in human history, challenges posed by syringe inspection become especially relevant while considering the ever-growing adoption of injectable drugs. These findings have led to the need of sophisticated inspection systems to help manufacturers address not only the coronavirus pandemic but also various other maladies.

While other containers such as cartridges, vials, and ampoules largely stand still and can enter the inspection process independently, syringes are typically carried via conveyor and then turned upside down. This has resulted in the need for robust inspection systems so that any hidden particles in the funnel can sink down into the liquid for increased inspection detectability.

Get a glimpse of the in-depth analysis through our Report Brochure

Manufacturers Expand Revenue Streams in Routine, Complex Injectable Products

The global generic injectables market is projected to clock a CAGR of 12.3% during the forecast period. Biological E Limited - an Indian biotechnology and biopharmaceutical company based in Hyderabad, Telangana, is gaining recognition for broadening its portfolio in 20 routine and complex injectable products. In order to establish stable revenue streams, companies are tapping into regulated markets and exploring other markets to generate income sources.

There is a growing demand for specialty generic injectables packaged in glass vials. Express Pharma in associated with West Pharma recently conducted a webinar to understand why emerging generic injectable manufacturers need flexibility and simplicity when dealing with drug delivery and containment.

FDA-approved Generic for Hypoglycemia Indicated for Radiologic Examination of Stomach

The generic injectables market is expected to cross US$ 307.7 Bn by 2031. The U.S. FDA (Food and Drug Administration) has approved the first generic of glucagon for injection USP for the treatment of severe hypoglycemia, which may occur in patients with diabetes mellitus. The drug has potentials as a diagnostic aid in the radiologic examination of the stomach, duodenum, small bowel, and colon in cases when diminished intestinal motility would be advantageous.

Companies in the generic injectables market are increasing their research to develop products meant for oncology and cardiology in order to expand their income sources.

generic injectables market segmentation

Expanding operations in future? To get the perfect launch ask for a custom report

Analysts’ Viewpoint

Apart from drug launches and price cuts, stakeholders in the generic injectables market are conducting webinars to understand how manufacturers are combating COVID-19 with the help of flexibility and simplicity during drug containment and delivery. Sun Pharmaceutical Industries Limited— an Indian multinational pharmaceutical company headquartered in Mumbai, India, is being publicized for its high quality generic and branded injectables available at affordable costs worldwide. However, syringes are among the most difficult containers to inspect and require handling protocols that are different from other primary packaging types. Stakeholders in the generic injectables market should adopt sophisticated inspection systems for gentle handling of syringes and avoiding glass-to-glass contact, which mitigates the likelihood of cracks or breakage.

Generic Injectables Market: Overview

  • This report analyzes the current scenario and future prospects of the global generic injectables market. Rise in prevalence of various diseases such as cancer, diabetes, and cardiac across the world, increase in demand for generic injectables, and surge in the geriatric patient pool are the key factors projected to drive the global generic injectables market during the forecast period.
  • The report provides an elaborate executive summary, including a snapshot of various segments of the global generic injectables market. It also provides elaborate information and data analysis of the global generic injectables market about segments based on product type, application, container type, route of administration, and region.
  • The overview section of the report provides a detailed qualitative analysis of drivers and restraints, and opportunities that impact the global generic injectables market
  • Additionally, the report includes company profiles which provide information about their business, product portfolios, and competitive landscape in the global generic injectables market
  • The report on the global generic injectables market offers market attractiveness analysis of the regions and segments
  • The last section of the report comprises quantitative and qualitative analysis on market share/position of key players operating in the global generic injectables market. It analyzes the key competitive strategies adopted by the major industry players, thereby presenting a thorough understanding of the competitive scenario in the global generic injectables market.

Generic Injectables Market: Key Segments

  • In terms of product type, the global generic injectables market has been bifurcated into large molecule injectables and small molecule injectables. The large molecule injectables segment held major share of the global generic injectables market in 2020, and the trend is anticipated to continue during the forecast period.
  • Based on application, the global generic injectables market has been classified into oncology, infectious diseases, cardiology, diabetes, immunology, and others. The oncology segment accounted for major share of the market in 2020.
  • In terms of container type, the global generic injectables market has been categorized into vials, premix, prefilled syringes, ampoules, and others
  • Based on route of administration, the global generic injectables market has been divided into intravenous, intramuscular, subcutaneous, and others
  • The market value and forecast for each of these segments have been provided from 2017 to 2031. The CAGRs of respective segments have also been provided from 2021 to 2031, considering 2017 to 2019 as the historical years and 2020 as base year.

Generic Injectables Market: Regional Outlook

  • In terms of region, the global generic injectables market has been segmented into North America (U.S. and Canada), Europe (U.K., Germany, Spain, Italy, France, and Rest of Europe), Asia Pacific (China, India, Japan, Australia & New Zealand, and Rest of Asia Pacific), Latin America (Brazil, Mexico, and Rest of Latin America), and Middle East & Africa (GCC Countries, South Africa, and Rest of Middle East & Africa). Each region considered in the market has been divided into countries/sub-regions.
  • The generic injectables market report provides value and forecast for each region and country/sub-region from 2017 to 2031. The compound annual growth rates (CAGRs) for each of these regions and countries have also been provided for the forecast period from 2021 to 2031. The generic injectables market study also covers the competitive scenario in these regions.

Companies Mentioned in Report

  • Key players in the global generic injectables market have been profiled based on attributes such as company overview, product portfolio, financial overview, recent developments, and competitive business strategies
  • Major companies profiled in the global generic injectables market report are
    • AstraZeneca
    • Baxter International, Inc.
    • Biocon
    • Fresenius SE & Co. KGaA
    • GlaxoSmithKline plc
    • Hikma Pharmaceuticals plc
    • Johnson & Johnson Services, Inc.
    • Lupin Ltd.
    • Merck KGaA
    • Mylan N.V.
    • Novartis AG (Sandoz International GmbH)
    • Pfizer, Inc.
    • Piramal Pharma Solutions
    • Sun Pharmaceutical Industries Ltd.
    • Teva Pharmaceutical Industries Ltd.

Generic Injectables Market – Segmentation

Product Type
  • Large Molecule Injectables
  • Small Molecule Injectables
Application
  • Oncology
  • Infectious Diseases
  • Cardiology
  • Diabetes
  • Immunology
  • Others
Container Type
  • Vials
  • Premix
  • Prefilled Syringes
  • Ampoules
  • Others
Route of Administration
  • Intravenous
  • Intramuscular
  • Subcutaneous
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Interested in this report?
Get a FREE sample now!

Get Free Sample

*Get Sample Report (PDF) sent to your email within minutes

Frequently Asked Questions

What is the total market worth of generic injectables market?

Generic injectables market is expected to cross US$ 307.7 Bn by 2031

What is the anticipated CAGR of the generic injectables market in the forecast period?

Generic injectables market is projected to clock a CAGR of 12.3% during 2021-2031

What are the key driving factors for the growth of the generic injectables market?

Generic injectables market is driven by rise in prevalence of various diseases and increase in demand for generic injectables

Which is the rising prominent segment in the generic injectables market?

The large molecule injectables segment held major share of the global generic injectables market in 2020, and the trend is anticipated to continue during the forecast period

Who are the key players in the global generic injectables market?

Key players in the market are Sanofi, Lupin Ltd., Biocon, Hikma Pharmaceuticals, Mylan N.V., Fresenius SE & Co

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary: Global Generic Injectables Market

4. Market Overview

    4.1. Introduction

        4.1.1. Product Type Definition

        4.1.2. Industry Evolution / Developments

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

    4.4. Global Generic Injectables Market Analysis and Forecast, 2017–2031

    4.5. Porter’s Five Force Analysis

5. Key Insights

    5.1. Key Industry Events (mergers, acquisitions, partnerships, collaborations, etc.)

    5.2. COVID-19 Pandemic Impact on Industry (value chain and short / mid /long term impact)

    5.3. Regulatory Scenario, by Region/globally

    5.4. Pipeline Analysis

    5.5. Disease Prevalence & Incidence Rate globally with key countries

6. Global Generic Injectables Market Analysis and Forecast, by Product Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Market Value Forecast, by Product Type, 2017–2031

        6.3.1. Large Molecule Injectables

            6.3.1.1. Monoclonal Antibodies (mAbs)

            6.3.1.2. Insulin

            6.3.1.3. Others

        6.3.2. Small Molecule Injectables

    6.4. Market Attractiveness Analysis, by Product Type

7. Global Generic Injectables Market Analysis and Forecast, by Application

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Market Value Forecast, by Application, 2017–2031

        7.3.1. Oncology

        7.3.2. Infectious diseases

        7.3.3. Cardiology

        7.3.4. Diabetes

        7.3.5. Immunology

        7.3.6. Others

    7.4. Market Attractiveness Analysis, by Application

8. Global Generic Injectables Market Analysis and Forecast, by Container Type

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Market Value Forecast, by Container Type, 2017–2031

        8.3.1. Vials

        8.3.2. Premix

        8.3.3. Prefilled Syringes

        8.3.4. Ampoules

        8.3.5. Others

    8.4. Market Attractiveness Analysis, by Container Type

9. Global Generic Injectables Market Analysis and Forecast, by Route of Administration

    9.1. Introduction & Definition

    9.2. Key Findings / Developments

    9.3. Market Value Forecast, by Route of Administration, 2017–2031

        9.3.1. Intravenous

        9.3.2. Intramuscular

        9.3.3. Subcutaneous

        9.3.4. Others

    9.4. Market Attractiveness Analysis, by Route of Administration

10. Global Generic Injectables Market Analysis and Forecast, by Region

    10.1. Key Findings

    10.2. Market Value Forecast, by Region

        10.2.1. North America

        10.2.2. Europe

        10.2.3. Asia Pacific

        10.2.4. Latin America

        10.2.5. Middle East & Africa

    10.3. Market Attractiveness Analysis, by Region

11. North America Generic Injectables Market Analysis and Forecast

    11.1. Introduction

        11.1.1. Key Findings

    11.2. Market Value Forecast, by Product Type, 2017–2031

        11.2.1. Large Molecule Injectables

            11.2.1.1. Monoclonal Antibodies (mAbs)

            11.2.1.2. Insulin

            11.2.1.3. Others

        11.2.2. Small Molecule Injectables

    11.3. Market Value Forecast, by Application, 2017–2031

        11.3.1. Oncology

        11.3.2. Infectious diseases

        11.3.3. Cardiology

        11.3.4. Diabetes

        11.3.5. Immunology

        11.3.6. Others

    11.4. Market Value Forecast, by Container Type, 2017–2031

        11.4.1. Vials

        11.4.2. Premix

        11.4.3. Prefilled Syringes

        11.4.4. Ampoules

        11.4.5. Others

    11.5. Market Value Forecast, by Route of Administration, 2017–2031

        11.5.1. Intravenous

        11.5.2. Intramuscular

        11.5.3. Subcutaneous

        11.5.4. Others

    11.6. Market Value Forecast, by Country, 2017–2031

        11.6.1. U.S.

        11.6.2. Canada

    11.7. Market Attractiveness Analysis

        11.7.1. By Product Type

        11.7.2. By Application

        11.7.3. By Container Type

        11.7.4. By Route of Administration

        11.7.5. By Country

12. Europe Generic Injectables Market Analysis and Forecast

    12.1. Introduction

        12.1.1. Key Findings

    12.2. Market Value Forecast, by Product Type, 2017–2031

        12.2.1. Large Molecule Injectables

            12.2.1.1. Monoclonal Antibodies (mAbs)

            12.2.1.2. Insulin

            12.2.1.3. Others

        12.2.2. Small Molecule Injectables

    12.3. Market Value Forecast, by Application, 2017–2031

        12.3.1. Oncology

        12.3.2. Infectious diseases

        12.3.3. Cardiology

        12.3.4. Diabetes

        12.3.5. Immunology

        12.3.6. Others

    12.4. Market Value Forecast, by Container Type, 2017–2031

        12.4.1. Vials

        12.4.2. Premix

        12.4.3. Prefilled Syringes

        12.4.4. Ampoules

        12.4.5. Others

    12.5. Market Value Forecast, by Route of Administration, 2017–2031

        12.5.1. Intravenous

        12.5.2. Intramuscular

        12.5.3. Subcutaneous

        12.5.4. Others

    12.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        12.6.1. Germany

        12.6.2. U.K.

        12.6.3. France

        12.6.4. Italy

        12.6.5. Spain

        12.6.6. Rest of Europe

    12.7. Market Attractiveness Analysis

        12.7.1. By Product Type

        12.7.2. By Application

        12.7.3. By Container Type

        12.7.4. By Route of Administration

        12.7.5. By Country/Sub-region

13. Asia Pacific Generic Injectables Market Analysis and Forecast

    13.1. Introduction

        13.1.1. Key Findings

    13.2. Market Value Forecast, by Product Type, 2017–2031

        13.2.1. Large Molecule Injectables

            13.2.1.1. Monoclonal Antibodies (mAbs)

            13.2.1.2. Insulin

            13.2.1.3. Others

        13.2.2. Small Molecule Injectables

    13.3. Market Value Forecast, by Application, 2017–2031

        13.3.1. Oncology

        13.3.2. Infectious diseases

        13.3.3. Cardiology

        13.3.4. Diabetes

        13.3.5. Immunology

        13.3.6. Others

    13.4. Market Value Forecast, by Container Type, 2017–2031

        13.4.1. Vials

        13.4.2. Premix

        13.4.3. Prefilled Syringes

        13.4.4. Ampoules

        13.4.5. Others

    13.5. Market Value Forecast, by Route of Administration, 2017–2031

        13.5.1. Intravenous

        13.5.2. Intramuscular

        13.5.3. Subcutaneous

        13.5.4. Others

    13.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        13.6.1. China

        13.6.2. India

        13.6.3. Japan

        13.6.4. Australia & New Zealand

    13.7. Market Attractiveness Analysis

        13.7.1. By Product Type

        13.7.2. By Application

        13.7.3. By Container Type

        13.7.4. By Route of Administration

        13.7.5. By Country/Sub-region

14. Latin America Generic Injectables Market Analysis and Forecast

    14.1. Introduction

        14.1.1. Key Findings

    14.2. Market Value Forecast, by Product Type, 2017–2031

        14.2.1. Large Molecule Injectables

            14.2.1.1. Monoclonal Antibodies (mAbs)

            14.2.1.2. Insulin

            14.2.1.3. Others

        14.2.2. Small Molecule Injectables

    14.3. Market Value Forecast, by Application, 2017–2031

        14.3.1. Oncology

        14.3.2. Infectious diseases

        14.3.3. Cardiology

        14.3.4. Diabetes

        14.3.5. Immunology

        14.3.6. Others

    14.4. Market Value Forecast, by Container Type, 2017–2031

        14.4.1. Vials

        14.4.2. Premix

        14.4.3. Prefilled Syringes

        14.4.4. Ampoules

        14.4.5. Others

    14.5. Market Value Forecast, by Route of Administration, 2017–2031

        14.5.1. Intravenous

        14.5.2. Intramuscular

        14.5.3. Subcutaneous

        14.5.4. Others

    14.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        14.6.1. Brazil

        14.6.2. Mexico

        14.6.3. Rest of Latin America

    14.7. Market Attractiveness Analysis

        14.7.1. By Product Type

        14.7.2. By Application

        14.7.3. By Container Type

        14.7.4. By Route of Administration

        14.7.5. By Country/Sub-region

15. Middle East & Africa Generic Injectables Market Analysis and Forecast

    15.1. Introduction

        15.1.1. Key Findings

    15.2. Market Value Forecast, by Product Type, 2017–2031

        15.2.1. Large Molecule Injectables

            15.2.1.1. Monoclonal Antibodies (mAbs)

            15.2.1.2. Insulin

            15.2.1.3. Others

        15.2.2. Small Molecule Injectables

    15.3. Market Value Forecast, by Application, 2017–2031

        15.3.1. Oncology

        15.3.2. Infectious diseases

        15.3.3. Cardiology

        15.3.4. Diabetes

        15.3.5. Immunology

        15.3.6. Others

    15.4. Market Value Forecast, by Container Type, 2017–2031

        15.4.1. Vials

        15.4.2. Premix

        15.4.3. Prefilled Syringes

        15.4.4. Ampoules

        15.4.5. Others

    15.5. Market Value Forecast, by Route of Administration, 2017–2031

        15.5.1. Intravenous

        15.5.2. Intramuscular

        15.5.3. Subcutaneous

        15.5.4. Others

    15.6. Market Value Forecast, by Country/Sub-region, 2017–2031

        15.6.1. GCC Countries

        15.6.2. South Africa

        15.6.3. Rest of Middle East & Africa

    15.7. Market Attractiveness Analysis

        15.7.1. By Product Type

        15.7.2. By Application

        15.7.3. By Container Type

        15.7.4. By Route of Administration

        15.7.5. By Country/Sub-region

16. Competition Landscape

    16.1. Market Player - Competition Matrix

    16.2. Market Share Analysis, by Company, 2020

    16.3. Competitive Business Strategies

    16.4. Company Profiles

        16.4.1. AstraZeneca

            16.4.1.1. Company Overview

            16.4.1.2. Company Financials

            16.4.1.3. Growth Strategies

            16.4.1.4. SWOT Analysis

        16.4.2. Baxter International, Inc.

            16.4.2.1. Company Overview

            16.4.2.2. Company Financials

            16.4.2.3. Growth Strategies

            16.4.2.4. SWOT Analysis

        16.4.3. Biocon

            16.4.3.1. Company Overview

            16.4.3.2. Company Financials

            16.4.3.3. Growth Strategies

            16.4.3.4. SWOT Analysis

        16.4.4. Fresenius SE & Co. KGaA

            16.4.4.1. Company Overview

            16.4.4.2. Company Financials

            16.4.4.3. Growth Strategies

            16.4.4.4. SWOT Analysis

        16.4.5. GlaxoSmithKline plc

            16.4.5.1. Company Overview

            16.4.5.2. Company Financials

            16.4.5.3. Growth Strategies

            16.4.5.4. SWOT Analysis

        16.4.6. Hikma Pharmaceuticals plc

            16.4.6.1. Company Overview

            16.4.6.2. Company Financials

            16.4.6.3. Growth Strategies

            16.4.6.4. SWOT Analysis

        16.4.7. Johnson & Johnson Services, Inc.

            16.4.7.1. Company Overview

            16.4.7.2. Company Financials

            16.4.7.3. Growth Strategies

            16.4.7.4. SWOT Analysis

        16.4.8. Lupin Ltd.

            16.4.8.1. Company Overview

            16.4.8.2. Company Financials

            16.4.8.3. Growth Strategies

            16.4.8.4. SWOT Analysis

        16.4.9. Merck KGaA

            16.4.9.1. Company Overview

            16.4.9.2. Company Financials

            16.4.9.3. Growth Strategies

            16.4.9.4. SWOT Analysis

        16.4.10. Mylan N.V.

            16.4.10.1. Company Overview

            16.4.10.2. Company Financials

            16.4.10.3. Growth Strategies

            16.4.10.4. SWOT Analysis

        16.4.11. Novartis AG (Sandoz International GmbH)

            16.4.11.1. Company Overview

            16.4.11.2. Company Financials

            16.4.11.3. Growth Strategies

            16.4.11.4. SWOT Analysis

        16.4.12. Pfizer, Inc.

            16.4.12.1. Company Overview

            16.4.12.2. Company Financials

            16.4.12.3. Growth Strategies

            16.4.12.4. SWOT Analysis

        16.4.13. Piramal Pharma Solutions

            16.4.13.1. Company Overview

            16.4.13.2. Company Financials

            16.4.13.3. Growth Strategies

            16.4.13.4. SWOT Analysis

        16.4.14. Sanofi

            16.4.14.1. Company Overview

            16.4.14.2. Company Financials

            16.4.14.3. Growth Strategies

            16.4.14.4. SWOT Analysis

        16.4.15. Sun Pharmaceutical Industries Ltd.

            16.4.15.1. Company Overview

            16.4.15.2. Company Financials

            16.4.15.3. Growth Strategies

            16.4.15.4. SWOT Analysis

        16.4.16. Teva Pharmaceutical Industries Ltd.

            16.4.16.1. Company Overview

            16.4.16.2. Company Financials

            16.4.16.3. Growth Strategies

            16.4.16.4. SWOT Analysis

List of Tables

Table 01: Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 02: Global Generic Injectables Market Value (US$ Mn) Forecast, by Large Molecule Injectables, 2017–2031

Table 03: Global Generic Injectables Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 04: Global Generic Injectables Market Value (US$ Mn) Forecast, by Container Type, 2017–2031

Table 05: Global Generic Injectables Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

Table 06: Global Generic Injectables Market Value (US$ Mn) Forecast, by Region, 2017–2031

Table 07: North America Global Generic Injectables Market Value (US$ Mn) Forecast, by Country, 2017–2031

Table 08: North America Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 09: North America Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 10: North America Global Generic Injectables Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 11: North America Global Generic Injectables Market Value (US$ Mn) Forecast, by Container Type, 2017–2031

Table 12: North America Global Generic Injectables Market Value (US$ Mn) Forecast, by Route of Administration , 2017–2031

Table 13: Europe Global Generic Injectables Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 14: Europe Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 15: Europe Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 16: North America Global Generic Injectables Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 17: Europe Global Generic Injectables Market Value (US$ Mn) Forecast, by Container Type, 2017–2031

Table 18: Europe Global Generic Injectables Market Value (US$ Mn) Forecast, by Route of Administration , 2017–2031

Table 19: Asia Pacific Global Generic Injectables Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 20: Asia Pacific Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 21: Asia Pacific Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 22: Asia Pacific Global Generic Injectables Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 23: Asia Pacific Global Generic Injectables Market Value (US$ Mn) Forecast, by Container Type, 2017–2031

Table 24: Asia Pacific Global Generic Injectables Market Value (US$ Mn) Forecast, by Route of Administration , 2017–2031

Table 25: Latin America Global Generic Injectables Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 26: Latin America Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 27: Latin America Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 28: Latin America Global Generic Injectables Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 29: Latin America Global Generic Injectables Market Value (US$ Mn) Forecast, by Container Type, 2017–2031

Table 30: Latin America Global Generic Injectables Market Value (US$ Mn) Forecast, by Route of Administration , 2017–2031

Table 31: Middle East & Africa Global Generic Injectables Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031

Table 32: Middle East & Africa Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 33: Middle East & Africa Global Generic Injectables Market Value (US$ Mn) Forecast, by Product Type, 2017–2031

Table 34: Middle East & Africa Global Generic Injectables Market Value (US$ Mn) Forecast, by Application, 2017–2031

Table 35: Middle East & Africa Global Generic Injectables Market Value (US$ Mn) Forecast, by Container Type, 2017–2031

Table 36: Middle East & Africa Global Generic Injectables Market Value (US$ Mn) Forecast, by Route of Administration, 2017–2031

List of Figures

Figure 01: Global Generic Injectables Market Value (US$ Mn) Forecast, 2017–2031

Figure 02: Global Generic Injectables Market Value Share, by Product Type, 2020

Figure 03: Global Generic Injectables Market Value Share, by Application, 2020

Figure 04: Global Generic Injectables Market Value Share, by Container Type, 2020

Figure 05: Global Generic Injectables Market Value Share, by Rout of Administration, 2020

Figure 06: Global Generic Injectables Market Value Share, by Region, 2020

Figure 07: Global Generic Injectables Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 08: Global Generic Injectables Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 09: Global Generic Injectables Market Revenue (US$ Mn), by Large Molecule Injectables, 2017–2031

Figure 10: Global Generic Injectables Market Revenue (US$ Mn), by Small Molecule Injectables, 2017–2031

Figure 11: Global Generic Injectables Market Value Share Analysis, by Application, 2020 and 2031

Figure 12: Global Generic Injectables Market Attractiveness Analysis, by Application, 2021–2031

Figure 13: Global Generic Injectables Market Revenue (US$ Mn), by Oncology, 2017–2031

Figure 14: Global Generic Injectables Market Revenue (US$ Mn), by Infectious Disease, 2017–2031

Figure 15: Global Generic Injectables Market Revenue (US$ Mn), by Cardiology, 2017–2031

Figure 16: Global Generic Injectables Market Revenue (US$ Mn), by Diabetes, 2017–2031

Figure 17: Global Generic Injectables Market Revenue (US$ Mn), by Immunology, 2017–2031

Figure 18: Global Generic Injectables Market Revenue (US$ Mn), by Others, 2017–2031

Figure 19: Global Generic Injectables Market Value Share Analysis, by Container Type, 2020 and 2031

Figure 20: Global Generic Injectables Market Attractiveness Analysis, by Container Type, 2021–2031

Figure 21: Global Generic Injectables Market Value (US$ Mn), by Vials, 2017–2031

Figure 22: Global Generic Injectables Market Value (US$ Mn), by Premix, 2017–2031

Figure 23: Global Generic Injectables Market Value (US$ Mn), by Prefilled Syringes, 2017–2031

Figure 24: Global Generic Injectables Market Value (US$ Mn), by Ampoules, 2017–2031

Figure 25: Global Generic Injectables Market Value (US$ Mn), by Others, 2017–2031

Figure 26: Global Generic Injectables Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 27: Global Generic Injectables Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 28: Global Generic Injectables Market Value (US$ Mn), by Intravenous, 2017–2031

Figure 29: Global Generic Injectables Market Value (US$ Mn), by Intramuscular, 2017–2031

Figure 30: Global Generic Injectables Market Value (US$ Mn), by Subcutaneous, 2017–2031

Figure 31: Global Generic Injectables Market Value (US$ Mn), by Others, 2017–2031

Figure 32: Global Generic Injectables Market Value Share Analysis, by Region, 2020 and 2031

Figure 33: Global Generic Injectables Market Attractiveness Analysis, by Region, 2021–2031

Figure 34: North America Global Generic Injectables Market Value (US$ Mn) Forecast, 2017–2031

Figure 35: North America Global Generic Injectables Market Value Share Analysis, by Country, 2020 and 2031

Figure 36: North America Global Generic Injectables Market Attractiveness Analysis, by Country, 2021–2031

Figure 37: North America Global Generic Injectables Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 38: North America Global Generic Injectables Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 39: North America Global Generic Injectables Market Value Share Analysis, by Application, 2020 and 2031

Figure 40: North America Global Generic Injectables Market Attractiveness Analysis, by Material, 2021–2031

Figure 41: North America Global Generic Injectables Market Value Share Analysis, by Container Type, 2020 and 2031

Figure 42: North America Global Generic Injectables Market Attractiveness Analysis, by Container Type, 2021–2031

Figure 43: North America Global Generic Injectables Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 44: North America Global Generic Injectables Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 45: Europe Global Generic Injectables Market Value (US$ Mn) Forecast, 2017–2031

Figure 46: Europe America Global Generic Injectables Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 47: Europe Global Generic Injectables Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 48: Europe Global Generic Injectables Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 49: Europe Global Generic Injectables Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 50: Europe Global Generic Injectables Market Value Share Analysis, by Application, 2020 and 2031

Figure 51: Europe Global Generic Injectables Market Attractiveness Analysis, by Material, 2021–2031

Figure 52: Europe Global Generic Injectables Market Value Share Analysis, by Container Type, 2020 and 2031

Figure 53: Europe Global Generic Injectables Market Attractiveness Analysis, by Container Type, 2021–2031

Figure 54: Europe Global Generic Injectables Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 55: Europe Global Generic Injectables Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 56: Asia Pacific Global Generic Injectables Market Value (US$ Mn) Forecast, 2017–2031

Figure 57: Asia Pacific Global Generic Injectables Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 58: Asia Pacific Global Generic Injectables Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 59: Asia Pacific Global Generic Injectables Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 60: Asia Pacific Global Generic Injectables Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 61: Asia Pacific Global Generic Injectables Market Value Share Analysis, by Application, 2020 and 2031

Figure 62: Asia Pacific Global Generic Injectables Market Attractiveness Analysis, by Material, 2021–2031

Figure 63: Asia Pacific Global Generic Injectables Market Value Share Analysis, by Container Type, 2020 and 2031

Figure 64: Asia Pacific Global Generic Injectables Market Attractiveness Analysis, by Container Type, 2021–2031

Figure 65: Asia Pacific Global Generic Injectables Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 66: Asia Pacific Global Generic Injectables Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 67: Latin America Global Generic Injectables Market Value (US$ Mn) Forecast, 2017–2031

Figure 68: Latin America Global Generic Injectables Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 69: Latin America Global Generic Injectables Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 70: Latin America Global Generic Injectables Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 71: Latin America Global Generic Injectables Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 72: Latin America Global Generic Injectables Market Value Share Analysis, by Application, 2020 and 2031

Figure 73: Latin America Global Generic Injectables Market Attractiveness Analysis, by Material, 2021–2031

Figure 74: Latin America Global Generic Injectables Market Value Share Analysis, by Container Type, 2020 and 2031

Figure 75: Latin America Global Generic Injectables Market Attractiveness Analysis, by Container Type, 2021–2031

Figure 76: Latin America Global Generic Injectables Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 77: Latin America Global Generic Injectables Market Attractiveness Analysis, by Route of Administration, 2021–2031

Figure 78: Middle East & Africa Global Generic Injectables Market Value (US$ Mn) Forecast, 2017–2031

Figure 79: Middle East & Africa Global Generic Injectables Market Value Share Analysis, by Country/Sub-region, 2020 and 2031

Figure 80: Middle East & Africa Global Generic Injectables Market Attractiveness Analysis, by Country/Sub-region, 2021–2031

Figure 81: Middle East & Africa Global Generic Injectables Market Value Share Analysis, by Product Type, 2020 and 2031

Figure 82: Middle East & Africa Global Generic Injectables Market Attractiveness Analysis, by Product Type, 2021–2031

Figure 83: Middle East & Africa Global Generic Injectables Market Value Share Analysis, by Application, 2020 and 2031

Figure 84: Middle East & Africa Global Generic Injectables Market Attractiveness Analysis, by Material, 2021–2031

Figure 85: Middle East & Africa Global Generic Injectables Market Value Share Analysis, by Container Type, 2020 and 2031

Figure 86: Middle East & Africa Global Generic Injectables Market Attractiveness Analysis, by Container Type, 2021–2031

Figure 87: Middle East & Africa Global Generic Injectables Market Value Share Analysis, by Route of Administration, 2020 and 2031

Figure 88: Middle East & Africa Global Generic Injectables Market Attractiveness Analysis, by Route of Administration, 2021–2031

Transparency Market Research Plus

Get a free copy if the report you purchased is updated within 90 days

Copyright © Transparency Market Research, Inc. All Rights reserved